Urinary Tract Infection Treatment Market SWOT Analysis Report 2021-2028 | Cipla Ltd, Bayer AG, Pfizer, GlaxoSmithKline

In most cases, complicated urinary tract infection is related to a structural or neurological disease that compromises the urinary tract or host defense. Factors related to the complicated urinary tract infection comprises pregnancy, chronic renal failure, immunosuppression, catheters, urinary retention, urine blockage, and transplantation, or other drainage devices. A simple urinary tract infection affects both the lower and upper parts of the bladder. It refers to nonresident infectious germs infecting the normal urinary tract.

Statistics

The global urinary tract infection treatment market is expected to be worth US$ 10,170.8 million in 2020 and is expected to reach US$ 11,827.8 million during the forecast period 2028.

To Get more Business Statergies Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1178

Global Urinary Tract Infection Treatment Market: Drivers

the global urinary tract infection market is expected to grow due to the approval and introduction of new drugs during the forecast period. For instance, Shionogi Inc. obtained U.S. Food and Drug Administration approval in November 2019 for Fetroja (cefiderocol), an antibacterial drug for the treatment of severe urinary tract infections in individuals 18 years of age and above.

Global Urinary Tract Infection Treatment Market: Opportunities

Urinary tract infection research and development is expected to provide attractive growth possibilities for companies in the global urinary tract infection treatment market. For instance, in October 2019, Aston University researchers reported that a phosphate glass composition comprising trace amounts of zinc oxide (ZnO) can help eliminate urinary tract infections that affect catheter patients.

Global Urinary Tract Infection Treatment Market: Restraints

low prices and short treatment duration are expected to restrict the global urinary tract infection treatment market growth over the forecast period. Antibiotics are commonly used to treat urinary tract infections, and around all of them are accessible in generic form, with generic antibiotics costing much less than branded antibiotics. Despite blood pressure or heart problems, which require patients to take medication for the rest of their lives, this therapy often lasts 1-2 weeks. Such factors are negatively affecting the market.

Key takeaways

The global urinary tract infection treatment market was worth US$ 9,971.9 million in 2019 and is expected to reach US$ 11,827.8 million by 2027, registering a CAGR of 2.2% during the forecast period of 2020 and 2027. The high incidence of urinary tract infection, as well as the availability of a variety of drugs, are the major factors driving the global urinary tract infection treatment market growth over the forecast period.

Quinolones accounted for the largest share in the global urinary tract infection treatment market in 2019, contributing to 37.7 % of the value, trailed by Cephalosporin and Penicillin & Combinations. The widespread use of quinolones in the treatment of urinary tract infections is promoting the growth of the segment.

To Get Research PDF Brochure Here @ https://www.coherentmarketinsights.com/insight/request-pdf/1178

Market trends

Key players in the global urinary tract infection treatment market are focusing on research and development of new therapies to increase their product offerings. For instance, Venatorx Pharmaceuticals began enrolment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections in August 2019.
According to research, preventive interventions may be ineffective in lowering the risk of catheter-related urinary tract infection problems. For instance, researchers from Baylor College of Medicine and the Veterans Affairs Medical Center in the U.S. reported in April 2020 that catheter-associated urinary tract infection problems can occur even when precautions are taken.

Global Urinary Tract Infection Treatment Market: Competitive Landscape

Some of the key players contributing to the global urinary tract infection treatment market are, Spero Therapeutics, Inc., Boehringer Ingelheim, Iterum Therapeutics plc, Shionogi Inc., Johnson & Johnson, Venatorx Pharmaceuticals, GlaxoSmithKline, Novartis AG, Cipla Ltd., Healthy.io, F. Hoffmann-La Roche Ltd., Allecra Therapeutics, Bayer AG, Pfizer Inc., and AstraZeneca Plc.

Global Urinary Tract Infection Treatment Market: Key Developments

June 2020: Iterum Therapeutics plc, a clinical-stage pharmaceutical company, reported that sulopenem did not achieve statistical non-inferiority relative to ertapenem in its SUlopenem for Resistant Enterobacteriaceae (SURE) phase 2 clinical trial in complicated urinary tract infection (cUTI).

Get Discount On The Purchase Of This Report @: https://www.coherentmarketinsights.com/promo/buynow/1178

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Coherent Market Insights :

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.